Effect of 4-Aminopyridine on Action Potential Parameters in Isolated Dog Purkinje Fibers

Archives of Drug Information

Volumn 3, Issue 1, 2010, Pages 19-25

  Thomas, George ^a   Klatt, Brian ^b   Blight, Andrew ^c  

^a ALCON RESEARCH LTD   (United States)

^b Calvert Laboratories Inc   (United States)

^c ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 Aminopyridine; Action Potential; Cardiac Effects; Fampridine; Purkinje Fibers; Torsades de Pointes

Indexed keywords

4 AMINOPYRIDINE; ION CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; IN VITRO STUDY; MALE; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT PROLONGATION; SAMPLE SIZE; TORSADE DES POINTES;

EID: 78851470335     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00027.x     Document Type: Article

References (38)

1. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, etal. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-95.
2. Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarisation and arrhythmias. News Physiol Sci 1997;12:152-57.
3. US Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/qtc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2005. Available at: (accessed June 12, 2009).
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals (ICH). ICH harmonised tripartite guideline: The clinical evaluation of QT/qtc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [Internet]. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals (ICH); 2005. Available at: (accessed June 12, 2009).
5. US Food and Drug Administration [Internet]. ICH S7B Guideline. Step 2 Revision. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2004. Available at: (accessed November 20, 2008).
6. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006;316:1098-106.
7. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, etal. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
8. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
9. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1996:92-5. Erratum in: M.C. Trudeau, J.W. Warmke, B. Ganetzky, G.A. Robertson, HERG sequence correction, Science 1996;272:087.
10. El-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res 1996;79:474-92.
11. El-Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Afterdepolarizations and ventricular arrhythmias. Circ Res 1988;63:286-305.
12. Nattel S, Quantz MA. Pharmacological response of quinidine induced early after depolarisations in canine cardiac Purkinje fibres: Insights into underlying ionic mechanisms. Cardiovasc Res 1988;22:808-17.
13. Roden DM. Early after-depolarizations and torsade de pointes: Implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 1993;14(suppl H):56-61.
14. Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, etal. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 2005;144:376-85.
15. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001;37:607-18.
16. Gralinski MR. The dog's role in the preclinical assessment of QT interval prolongation. Toxicol Pathol 2003;31(suppl 1):11-6.
17. Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, etal. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41.
18. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, etal. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68.
19. Polman CH, Bertelsmann FW, Van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:292-6.
20. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21.
21. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59.
22. Stuhmer W, Ruppersberg JP, Schroter KH, Sakmann B, Stocker M, Giese KP, etal. Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain. EMBO J 1989;8:3235-44.
23. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61.
24. Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978;153:307-18.
25. Renganathan M, Sidach S, Blight AR. Effects of 4-aminopyridine on cloned hERG channels expressed in mammalian cells. Arch Drug Inf 2009;2:51-7.
26. Kenyon JL, Gibbons WR. 4-Aminopyridine and the early outward current of sheep cardiac Purkinje fibers. J Gen Physiol 1979;73:139-57.
27. Han W, Wang Z, Nattel S. A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. Am J Physiol Heart Circ Physiol 2000;279:H466-74.
28. Nattel S, Matthews C, De Blasio E, Han W, Li D, Yue L. Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs. Potential relevance to ionic mechanisms in vivo. Circulation 2000;101:1179-84.
29. Boyett MR. Effect of rate-dependent changes in the transient outward current on the action potential in sheep Purkinje fibres. J Physiol 1981;319:23-41.
30. Cordeiro JM, Spitzer KW, Giles WR. Repolarizing K+ currents in rabbit heart Purkinje cells. J Physiol 1998;508(Pt 3):811-23.
31. Patel SP, Campbell DL. Transient outward potassium current, "Ito", phenotypes in the mammalian left ventricle: Underlying molecular, cellular and biophysical mechanisms. J Physiol 2005;569:7-39.
32. Sun X, Wang HS. Role of the transient outward current (Ito) in shaping canine ventricular action potential: A dynamic clamp study. J Physiol 2005;564:411-9.
33. Sridhar A, Da Cunha DN, Lacombe VA, Zhou Q, Hamlin RL, Carnes CA. The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol 2007;152:870-9.
34. Robinson RB, Liu QY, Rosen MR. Ionic basis for action potential prolongation by phenylephrine in canine epicardial myocytes. J Cardiovasc Electrophysiol 2000;11:70-6.
35. Varro A, Balati B, Iost N, Takacs J, Virag L, Lathrop DA, etal. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol 2000;523(Pt 1):67-81.
36. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-82.
37. Witchel HJ. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 2007;11:321-36.
38. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, etal. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-41.